← Blog

Credential Landscape & Vendor Archive Series

Integrated Dual Disorder Treatment (IDDT), Robert Drake, and the Dartmouth Psychiatric Research Center: Credential Landscape, Cloud AI Scribe Vendor Archive Record Types, and the HIPAA Privilege Gap

September 26, 2026 · TherapyDraft · 5,800 words

1. Robert Drake, the Dartmouth Psychiatric Research Center, and the institutional landscape of IDDT

Integrated Dual Disorder Treatment was developed over roughly a decade at the Dartmouth Psychiatric Research Center — a research unit of Dartmouth Medical School, now the Geisel School of Medicine at Dartmouth — principally by Robert Drake, Kim Mueser, Gary Bond, and their colleagues. The developmental arc of IDDT runs from the late 1980s through the early 2000s. Drake, Mercer-McFadden, Mueser, McHugo, and Bond published a systematic review of controlled studies of integrated treatment for dual disorders in Psychiatric Services in 1998 that established the empirical foundation for the model. Drake, Essock, Shaner, Carey, Minkoff, Kola, Lynde, Osher, Clark, and Rickards published a landmark consensus statement in Psychiatric Services in 2001 outlining the principles of integrated dual disorders treatment and the barriers to its implementation in the existing mental health system. By 2003, SAMHSA had packaged IDDT into a comprehensive federal dissemination resource — the Integrated Dual Disorder Treatment Implementation Resource Kit (IDDT KIT) — distributed to state mental health authorities across the country.

The conceptual foundation of IDDT rests on a straightforward empirical observation that Drake, Mueser, and colleagues documented extensively: rates of substance use disorder among adults with severe mental illness — schizophrenia, bipolar disorder, and schizoaffective disorder — are dramatically elevated compared to the general population, typically running two to five times higher. Prior to IDDT, the standard service system response was either sequential (treat the SMI first, then the SUD) or parallel (maintain separate mental health treatment and substance use treatment in separate, uncoordinated systems). Both approaches failed the co-occurring population systematically. Sequential treatment left patients managing substance use without clinical support during the mental health treatment phase. Parallel treatment created two separate treatment relationships with conflicting recommendations, conflicting medication policies (12-step programs' opposition to psychiatric medications directly undermined adherence to antipsychotics), and no shared clinical picture of the patient across the two conditions. IDDT’s core innovation was to integrate both within the same treatment team, using the same treating clinicians, in the same service encounter.

Dartmouth College is a private Ivy League research university incorporated under New Hampshire law and governed by the Dartmouth Board of Trustees. It holds no governmental regulatory authority of any kind over the clinical practice of licensed mental health professionals in New Hampshire or any other state. The Dartmouth Psychiatric Research Center — which functioned as the primary research and development home for IDDT — is a research unit of a private university. It has no sovereign regulatory authority over practitioners who deliver IDDT, no authority to impose mandatory credentialing requirements on licensed clinicians, and no status as a health oversight agency under HIPAA § 164.512(d). A private university research center’s role in developing and disseminating an evidence-based practice — however extensive that role, however large the federal research portfolio, however widely the practice was adopted — confers no governmental regulatory character on the center or on the treatment.

SAMHSA’s role in IDDT dissemination was substantial. The IDDT KIT was a multivolume federal resource distributed by SAMHSA’s Center for Mental Health Services (CMHS) as part of the Evidence-Based Practices Implementation Resource Kit series — a broader federal effort to disseminate evidence-based practices to state mental health systems. State mental health authorities received the KITs and were encouraged to incorporate IDDT into their service systems. Individual clinicians and programs received training through SAMHSA-funded training events, state authority initiatives, and federally funded technical assistance programs. None of these dissemination mechanisms creates § 164.512(d) authority over practitioners who received the KIT materials and implemented IDDT principles. SAMHSA’s governmental authority extends to the organizations it funds as grantees through cooperative agreements; it does not extend to the universe of clinicians who have implemented a practice that SAMHSA helped disseminate. A certified community support specialist at a community mental health center who uses IDDT’s stage-based assessment and integrated treatment principles in their daily practice without being employed at a SAMHSA-funded grantee organization is not subject to SAMHSA’s oversight authority through the IDDT KIT dissemination network.

There is no IDDT Institute equivalent to the DBT-Linehan Board of Certification or the EMDR International Association. There is no IDDT board certification issued by any governmental or quasi-governmental professional body. There is no mandatory IDDT practitioner registry. State mental health licensing boards — not Dartmouth, not the Dartmouth Psychiatric Research Center, not SAMHSA — are the governmental entities with regulatory authority over licensed practitioners’ clinical practice.

Primary evidence base: Mueser, Drake, Clark, McHugo, Mercer-McFadden, and Ackerson (SAMHSA, 1995) provided the initial IDDT model description. Drake, Mercer-McFadden, Mueser, McHugo, and Bond (Psychiatric Services, 1998) established the systematic evidence base through a review of controlled studies. Drake, McHugo, Xie, Fox, Packard, and Helmstetter (Psychiatric Services, 2006) reported the New Hampshire IDDT fidelity and outcome study. Mueser, Torrey, Lynde, Singer, and Drake (Journal of Dual Diagnosis, 2003) described IDDT’s implementation principles and components. The Osher and Kofoed four-stage model (Psychiatric Services, 1989) underpins IDDT’s stage-based assessment and treatment planning framework. The Dartmouth Assessment of Lifestyle Instrument (DALI) — developed specifically for use with the SPMI population — was validated by Rosenberg, Drake, Wolford, Mueser, Oxman, Vidaver, Carrieri, and Luckoor (American Journal of Psychiatry, 1998) as the specialized substance use screen for people with severe mental illness.

2. IDDT’s stage-based integrated framework: structural logic for the four novel record types

To understand why IDDT generates four vendor archive record types structurally absent from all 235 prior posts in this series, it is necessary to understand IDDT’s core structural features — specifically the combination of elements that distinguishes it from every treatment in the 236-post corpus, including the most similar treatment in the series, Seeking Safety (post #235).

IDDT’s defining structural features are: (1) it is specifically designed for adults with severe mental illness — schizophrenia, bipolar disorder, schizoaffective disorder — with co-occurring SUD, meaning its assessments document SMI psychosis content (specific delusional beliefs, specific hallucination types and command content) as primary clinical variables rather than PTSD trauma history; (2) it organizes treatment around the Osher-Kofoed four-stage model, making the patient’s current motivational stage a documented primary clinical variable that determines which clinical intervention is appropriate at a given treatment point; (3) its primary service delivery vehicle is Assertive Community Treatment — a multidisciplinary team delivering services in community settings — making the ACT team meeting a structurally central record type with multiple treating providers simultaneously contributing to a single shared patient document; and (4) it integrates SMI treatment and SUD treatment within the same team and the same clinical record at every treatment stage, creating dual-disorder documentation across the entire clinical record rather than at just the intake assessment.

The difference from Seeking Safety (post #235) is structurally fundamental. Seeking Safety documents co-occurring PTSD and SUD for a broadly accessible outpatient population without requiring the ACT team delivery structure, without the stage-based motivational framework, and without severe mental illness as the defining diagnostic context. IDDT documents co-occurring severe mental illness — specifically the psychotic disorders and bipolar spectrum — and SUD for the highest-needs segment of the public mental health population, organized around the Osher-Kofoed stages and typically delivered through the ACT team structure. The clinical records these two treatments generate are structurally different in what they document (PTSD trauma history versus SMI psychosis content), how they organize treatment (safe coping topic versus motivational stage), how they deliver services (individual/group outpatient versus ACT team community-based), and what team structure produces the documentation (one clinician versus a multidisciplinary team).

These four structural features together generate the four novel vendor archive record types analyzed in the following sections.

3. IDDT stage-based integrated dual-diagnosis assessment narration: SMI symptom content and motivational stage as co-equal clinical variables

The IDDT stage-based integrated dual-diagnosis assessment narration is the vendor archive record of IDDT’s intake procedure — the structured clinical assessment through which the clinician simultaneously characterizes the patient’s severe mental illness symptom profile, their substance use disorder profile, and their current Osher-Kofoed motivational stage, all within a single integrated assessment document.

The severe mental illness component covers the patient’s primary Axis I diagnosis and its current symptomatic expression in clinical detail. For patients with schizophrenia or schizoaffective disorder, the intake assessment documents the specific current positive symptoms: whether the patient is experiencing auditory hallucinations, and if so their frequency, content, whether they are command hallucinations and if so what commands are being issued; whether the patient holds active delusional beliefs, and if so the specific content and organization of those beliefs — the specific nature of a persecutory delusion (who the patient believes is persecuting them and how), the specific content of a referential delusion, the specific elements of a grandiose delusion. The assessment also documents negative symptom severity: degree of flat affect in the clinical interview, degree of avolition and loss of goal-directed activity, anhedonia, alogia, and social withdrawal. For patients with bipolar disorder, the assessment covers the current mood episode phase (depressed, manic, hypomanic, mixed, euthymic), historical episode count and duration, onset age, the most severe historical episodes (hospitalizations, suicide attempts, arrest histories associated with manic episodes), and the functional consequences of the disorder across employment, relationships, and housing. For patients with schizoaffective disorder, the assessment covers both the psychosis components and the mood episode history.

The SUD component documents the patient’s substance use profile within the specific clinical context of the SPMI population. The Dartmouth Assessment of Lifestyle Instrument (DALI) — developed specifically for people with severe mental illness — may be used as part of the SUD component, documenting the patient’s self-reported substance use frequency and the degree to which substance use has caused problems in a clinically accessible format suited to cognitive limitations that some patients with SMI experience. Beyond the DALI, the full SUD assessment documents which substances are involved (alcohol, cannabis, cocaine, amphetamines, opioids, sedatives, multiple substances in combination), the pattern’s temporal structure including onset relative to the SMI symptoms, current use frequency and quantity, the patient’s own account of the functional relationship between the substance use and the SMI — the specific perceived benefits (self-medication of symptoms, social belonging, management of medication side effects) and costs (symptom exacerbation, medication interference, crisis hospitalization risk) as the patient reports understanding them.

The Osher-Kofoed motivational stage component documents the patient’s current stage as a named clinical variable: Engagement (not yet consistently connected to treatment), Persuasion (connected but not motivated to address the SUD), Active Treatment (actively working on reducing or stopping substance use), or Relapse Prevention (sustained reduction or abstinence maintained, focused on preventing recurrence). The stage assignment is not informal — it is a documented clinical determination based on specific behavioral and attitudinal criteria in the Osher-Kofoed framework — and it directly determines which clinical interventions are appropriate. A patient at the Persuasion stage receives motivational interviewing; a patient at the Active Treatment stage receives specific coping skills, assertiveness training, and social support building; a patient at the Relapse Prevention stage receives an integrated relapse prevention plan covering both SMI management and SUD relapse risk.

This record is the only intake assessment in 236 posts that simultaneously documents specific SMI psychosis content (including specific delusional belief content and specific command hallucination commands), a specific SUD profile, and a named motivational stage on a published framework as co-equal primary clinical organizing variables in the same intake document. The specific psychosis symptom content documented — the content of the patient’s current delusions, the commands being issued by command hallucinations, the specific patterns of paranoid ideation — is sensitive clinical information that appears in the vendor archive as structured primary assessment content. When a cloud AI scribe narrates the IDDT intake session and that narration is maintained in the vendor’s archive, the vendor holds a business record containing the specific content of the patient’s current psychotic symptoms alongside their substance use profile and their motivational stage assessment, all in a single document.

4. IDDT persuasion stage motivational session narration: motivational stage as session-level clinical content variable

The IDDT persuasion stage motivational session narration is the vendor archive record of sessions conducted with patients at the Persuasion stage of the Osher-Kofoed framework — sessions in which the primary clinical task is motivational engagement with the patient’s ambivalence about their substance use, using motivational interviewing techniques integrated within the IDDT clinical framework.

At the Persuasion stage, the patient is consistently connected to treatment — they are showing up for case management, for medication appointments, for community support services — but they have not acknowledged the substance use as a problem they want to address. The standard clinical response in parallel or sequential treatment systems was to confront or exhort the patient to stop using, a response that typically increased resistance, damaged the therapeutic relationship, and drove patients out of treatment. IDDT’s response was to deploy motivational interviewing at the Persuasion stage with specific clinical modifications appropriate for the SPMI population: lower confrontation level (higher resistance in this population to direct confrontation), longer persuasion phase (change may take months or years), and explicit integration of the SMI clinical content into the motivational work rather than treating substance use in isolation.

The session is organized around the clinician’s use of MI-consistent techniques: open-ended exploration of the patient’s perceived role of substance use in their life, reflective listening to the patient’s account of what they get from using, collaborative exploration of the discrepancy between substance use and the patient’s own stated goals, and strategic elicitation of change talk. The session narration documents the specific techniques deployed, the specific content of the patient’s expressed ambivalence, and any change talk the patient produced — the patient’s own statements of dissatisfaction with the current situation, acknowledgment of substance use costs, or interest in change.

The structural novelty of this record in the 236-post series lies in the integration of the motivational stage variable and the SMI clinical content as simultaneous clinical content in the session narration. The persuasion stage session for an IDDT patient explores the specific relationship between the patient’s substance use and their SMI symptoms as the patient currently understands it. The decisional balance in this context involves the patient’s perceived benefits of substance use — which may specifically include relief from negative SMI symptoms (anhedonia, social withdrawal, flat affect), perceived management of positive symptoms (the patient’s account of whether and how substance use affects their hallucinations or paranoia), social connection in using networks that provide structure for patients whose SMI has disrupted other social connections, and perceived mitigation of medication side effects (patients on antipsychotics with significant weight gain, sexual dysfunction, or sedation side effects sometimes report using stimulants or cannabis to counteract these effects). The session narration documents the patient’s specific account of the perceived relationship between their SMI and their substance use — including specific descriptions of how they perceive the substances affecting their hallucinations, delusions, or mood — alongside the clinician’s MI-consistent response to each element of that account.

This creates a vendor archive record in which the patient’s specific SMI symptom experience — the specific hallucinations they are currently experiencing and the patient’s own account of how substance use affects them, the specific delusional beliefs and their functional role in the patient’s daily life — appears alongside the patient’s substance use account and the session’s motivational work in a single business document. The patient’s change talk — including statements of ambivalence, concern, or readiness that the patient made in the MI context — appears in the vendor archive as structured clinical content at a specific session date. This is structurally distinct from every prior session record in the 236-post series: no prior record type documents the motivational stage on a named stage-based framework as the session-level organizing clinical variable, and no prior record documents the patient’s own account of the perceived relationship between their SMI psychosis symptoms and their substance use as the primary motivational session content.

5. IDDT ACT team integrated community meeting narration: multiple treating providers in one business record

The IDDT ACT team integrated community meeting narration is the vendor archive record of the multidisciplinary Assertive Community Treatment team meeting — the structured clinical coordination meeting in which all members of the patient’s ACT team simultaneously contribute clinical updates about the patient’s SMI status, substance use behavior, community functioning, medication adherence, housing stability, and crisis history to a single shared team meeting document.

Assertive Community Treatment is IDDT’s primary service delivery vehicle. ACT is not simply a coordination mechanism for existing services — it is a comprehensive treatment system in which a small multidisciplinary team takes shared, undivided responsibility for all of a patient’s mental health and substance use disorder treatment needs, delivering services in the patient’s home, neighborhood, and community rather than in office-based clinical settings. The ACT team for a given patient typically includes: a team leader (usually a master’s-level clinician), a psychiatrist (shared across the full caseload, typically 80–120 patients), a registered nurse who manages medications and injection schedule, case managers who provide the majority of direct service contact, a substance use disorder specialist, a vocational rehabilitation specialist, and peer support specialists (people with lived experience of SMI and recovery). The team meets daily — typically a morning standup — to review all patients, with more extended discussions of patients with active clinical concerns.

The ACT team daily meeting review for a given patient draws simultaneously on all team members’ observations and assessments from the prior 24 hours or since the last meeting. The psychiatrist reports on medication response and any needed medication adjustment. The nurse reports on whether the patient received their medications on schedule, any side effect concerns, and the next long-acting injectable appointment if applicable. The case manager who made the most recent community contact reports on the patient’s current housing situation, food security, benefits status, family contact, and observed behavioral state. The substance use specialist reports on the patient’s current Osher-Kofoed stage, any substance use events reported or observed, and the status of the current motivational work or active treatment plan. The peer support specialist reports on the patient’s social engagement and self-reported daily experience from a recovery perspective. When a cloud AI scribe narrates the ACT team meeting — either by processing the team discussion in real time or by synthesizing the individual team members’ notes into an integrated team meeting record — the vendor archive contains a business document in which all of these simultaneously contributed clinical updates appear in one record.

The structural novelty of this record in the 236-post series is the multi-provider single-document structure. Every prior record type in the series — all 235 prior posts — documents a dyadic or group encounter led by a single treating clinician. The individual therapy sessions document one clinician and one patient. The family therapy sessions (BSFT post #233, FFT post #229, MDFT post #231, MST post #230) document one clinician (or one clinician team using a single shared framework) and one family. The group therapy sessions document one clinician conducting the group. The ACT team meeting narration is the only record type in 236 posts in which multiple treating providers — a psychiatrist, a nurse, multiple case managers, a substance use specialist, a peer support specialist — simultaneously contribute independent clinical assessments of the same patient from their respective roles and disciplines to a single shared business record maintained in the vendor archive. The combined document contains the psychiatrist’s current medication assessment alongside the case manager’s housing stability report alongside the substance use specialist’s SUD stage assessment alongside the nurse’s medication adherence note, all as structured clinical content about the same patient in the same vendor-archived business record.

The multi-provider structure also creates specific questions about privilege and disclosure. Different team members may hold different licensing credentials: the psychiatrist is licensed as an MD, the nurse as an RN, the case managers may hold master’s-level clinical licenses, the peer support specialist typically holds certification rather than a clinical license, and the substance use specialist may hold either a licensed counselor credential or an addiction counselor certification that may or may not create psychotherapist-patient privilege under the applicable state statute. When a single team meeting business record in the vendor archive combines all of these providers’ clinical contributions, the scope of any psychotherapist-patient privilege applicable to the combined record is legally uncertain: the privilege may apply to the portions contributed by licensed providers but not to the portions contributed by certified peer support specialists or unlicensed case managers, but the vendor archive may maintain the record as a single inseparable document rather than segmented by contributor.

6. IDDT integrated relapse analysis narration: temporally linked SMI and SUD relapse in one clinical document

The IDDT integrated relapse analysis narration is the vendor archive record of the structured clinical procedure through which IDDT clinicians analyze a co-occurring relapse episode — an episode in which both a psychiatric crisis or psychotic decompensation event and a substance use relapse event occurred within a proximate time window — to identify the specific triggers, warning signs, sequence of events, and causal mechanisms that linked the two events, and to develop an integrated relapse prevention plan addressing both conditions simultaneously.

In IDDT’s integrated relapse prevention framework, psychiatric relapse and SUD relapse are analyzed together rather than separately because they are clinically interrelated in the SPMI population. Substance use reliably precipitates psychotic decompensation in patients with schizophrenia and schizoaffective disorder — stimulants and cannabis are particularly well-documented as precipitants of psychosis in this population. Conversely, prodromal psychotic symptoms — increased anxiety, perceptual distortions, emerging paranoia, sleep disruption — reliably precipitate substance use in patients who use substances to self-medicate early psychosis symptom emergence. In bipolar disorder, stimulant use precipitates manic episodes, and the impulsivity of manic episodes increases substance use. In schizoaffective disorder, both pathways operate simultaneously. The IDDT integrated relapse analysis is the clinical procedure that characterizes which pathway was operative in a specific co-occurring relapse episode for a specific patient.

The integrated relapse analysis narration documents: the specific sequence of events in the co-occurring relapse episode — when did prodromal signs first appear, when did the substance use episode occur, when did the psychiatric crisis manifest, what was the temporal relationship between the two, which occurred first and what evidence supports that sequencing; the specific substances used in the episode (which substances, approximate quantities, approximate dates, the social context of the use episode); the specific psychiatric symptoms that emerged or worsened (the specific delusional content that developed, the specific hallucination content that intensified, the specific mood episode features that appeared); the specific early warning signs that were present before the crisis that the patient or team members observed in retrospect; the specific triggers — external stressors, medication adherence problems, social disruptions, identified prodromal cues — that preceded both components of the co-occurring episode; and the specific integrated relapse prevention plan that the analysis generates, covering both the SMI management components (medication adherence monitoring, prodromal sign recognition, crisis contact plan) and the SUD relapse prevention components (high-risk situation identification, coping skill deployment, social support mobilization).

The integrated relapse analysis narration is the only vendor archive session record in 236 posts organized around the retrospective analysis of a temporally linked co-occurring episode in which both an SMI psychiatric crisis and an SUD substance use episode are analyzed as causally connected events in the same clinical document. Seeking Safety’s between-session check-in (post #235) documents ongoing interval behavioral events in both the PTSD and SUD domains — but prospectively and as interval documentation, not as a structured retrospective analysis of a specific linked co-occurring episode. The DBT-SUD behavioral chain analysis (post #220) analyzes a specific target behavior through the behavioral chain mechanism — but within the single-disorder DBT framework, not as a temporal linkage analysis between a psychiatric crisis event and a substance use event. The A-CRA functional analysis (post #232) organizes substance use through the ABC mechanism but does not involve a psychiatric crisis event as a linked component. The IDDT integrated relapse analysis is the only record in 236 posts that makes the causal linkage between a psychiatric crisis episode and a substance use episode the primary clinical content of the session — documenting the specific sequence in which they unfolded, the specific SMI symptom content of the psychiatric component, the specific substances and contexts of the SUD component, and the specific prevention plan addressing both components in an integrated framework.

7. Five adversarial proceedings

State licensing board complaints from unlicensed IDDT practitioners. IDDT is delivered by a range of practitioners across the ACT team structure who may not hold qualifying state mental health licenses creating psychotherapist-patient privilege. Peer support specialists — a core component of the ACT team model — typically hold state certification as peer recovery specialists or certified peer specialists rather than a clinical licensure credential. The peer support specialist’s contributions to ACT team meeting records and their individual community contact notes with patients are clinical documentation created outside the scope of a qualifying professional license. Case managers employed in ACT programs frequently hold bachelor’s or master’s degrees in social work, counseling, or human services with varying levels of licensure; case managers without a qualifying clinical license create documentation outside the scope of psychotherapist-patient privilege even when their documentation is substantive in its clinical content. When these practitioners’ contributions are integrated into a cloud AI scribe vendor archive record — whether through individual contact notes or through the team meeting narration — those records document clinical activities in third-party-maintained business records accessible through subpoena.

State licensing board investigations of unlicensed practice use session-by-session clinical documentation — precisely what the vendor archive preserves — to establish that the practitioner was conducting clinical assessment and treatment activities outside the scope of their credential. The IDDT stage-based assessment narration documents structured clinical assessment of severe mental illness and substance use disorder by practitioners whose license level may not authorize clinical assessment or mental health treatment. The persuasion stage session narrations document structured psychotherapeutic intervention (motivational interviewing for co-occurring disorders). The ACT team meeting narrations document clinical decision-making involving medication management, psychiatric hospitalization decisions, and crisis planning by a team whose clinical contributions are combined in a single record regardless of individual team members’ licensing status.

Civil commitment, involuntary hospitalization, and mental health court proceedings. IDDT’s target population — adults with severe mental illness and co-occurring SUD — is substantially represented among the population subject to civil commitment proceedings, emergency involuntary psychiatric hospitalization, and mental health court diversion programs. The IDDT stage-based integrated dual-diagnosis assessment narration documents the specific content of the patient’s current psychosis symptoms — including the specific delusional beliefs (their content, their organization, the specific people or entities the patient identifies in persecutory or referential delusions), the specific command hallucination content (the specific commands the patient reports being issued), and the specific behavioral consequences of those symptoms in the patient’s recent history — in a vendor-archived business record that is the most clinically specific characterization of the patient’s current psychosis available outside the treating clinician’s own medical records.

In a civil commitment proceeding, the petitioner — typically a family member, a mental health professional, or the treating psychiatrist — must establish that the patient meets the statutory criteria for commitment: danger to self or others, or grave disability as defined by the applicable state statute. The IDDT assessment narration’s documentation of specific command hallucination content, specific delusional beliefs with specific named individuals, and specific recent behavioral consequences of SMI symptoms in the context of active substance use constitutes precisely the kind of clinical evidence relevant to the commitment criteria determination. The integrated relapse analysis narration may additionally document recent co-occurring episodes in which psychiatric decompensation was directly linked to substance use — documenting the specific events, the specific timeline, the patient’s behavioral state during the episode — as structured clinical content in the vendor archive. Parties to a civil commitment proceeding, or an attorney ad litem appointed for the patient, may subpoena the cloud AI scribe vendor for the complete IDDT record as evidence of the patient’s clinical history and current symptom status. The patient may not be in a position to contest the subpoena, instruct their own attorney about the vendor archive’s existence, or know that their clinical disclosures from IDDT treatment sessions are being used as evidence in the commitment hearing.

SSA disability and DAA materiality proceedings. Social Security disability determinations involving claims by adults with severe mental illness and co-occurring SUD require the Social Security Administration to apply the Drug Addiction and Alcoholism (DAA) materiality analysis — the statutory requirement that if an applicant’s drug addiction or alcoholism is a contributing factor material to the determination of disability, the SSA may not find the applicant disabled. The DAA materiality analysis requires the adjudicator to determine whether the claimant would still be disabled if they stopped using drugs or alcohol. This determination requires a clinical assessment of the claimant’s impairment from the SMI independently of the contribution of substance use — a question that the IDDT integrated dual-diagnosis assessment addresses directly: by simultaneously characterizing both the SMI symptom profile and the SUD profile in the same document, and by documenting the clinician’s assessment of the functional relationship between the two (the degree to which substance use exacerbates the SMI versus the degree to which the SMI persists independently of substance use), the IDDT assessment narration is precisely the kind of clinical document an SSA adjudicator or a reviewing judge needs to apply the DAA materiality standard.

The IDDT integrated relapse analysis narration is similarly relevant to the DAA materiality question: it documents the specific causal relationship between substance use and psychiatric decompensation episodes in the patient’s clinical history — which direction the causal pathway ran, what the SMI symptom baseline was between episodes, and what the prognosis would be with substance use cessation. SSA litigating arms, including claimant representatives and the Office of Disability Adjudication and Review, may seek this documentation through subpoena to the cloud AI scribe vendor as evidence relevant to the DAA materiality determination — documentation that the patient’s treating team produced in the clinical context without awareness that it would be central to a federal disability determination proceeding.

Housing court, HUD, and supportive housing compliance proceedings. IDDT’s target population is disproportionately represented in supportive housing programs — permanent supportive housing for people with severe mental illness, HUD Section 811 housing for people with disabilities, state-operated community residences, and various housing-first program models. These housing programs typically impose behavioral conditions on participants: no active substance use on the premises, no behavior that disturbs other residents, compliance with medication schedules, participation in required treatment. Violations of these conditions can result in eviction proceedings, loss of the housing subsidy, or transfer to a higher level of supervised housing.

The IDDT integrated relapse analysis narration documents the patient’s specific co-occurring relapse episodes — which substances were involved, the specific dates, the behavioral events that accompanied the episode, and the community setting in which the substance use occurred. The ACT team meeting narrations document the team’s ongoing assessment of the patient’s housing stability, any substance use events observed or reported during community contacts at the patient’s home, and the team’s housing-related interventions. The persuasion stage session narrations document the patient’s current motivational stage and their ongoing substance use. In a housing court eviction proceeding for a supportive housing tenant, or in a housing program compliance review determining whether a participant should lose their Section 811 subsidy, the housing program operator may subpoena the cloud AI scribe vendor for the patient’s IDDT treatment records — obtaining a session-by-session documentation of the patient’s substance use trajectory, the team’s community-based observations of the patient’s housing behavior, and the specific co-occurring relapse episodes that the housing program may be citing as violations of the program conditions. These records are maintained in the vendor archive as business records of the treating team, not as the patient’s own medical records, and the patient may have no opportunity to review them before they are produced in the housing proceeding.

Criminal justice, mental health diversion, and criminal defense proceedings involving the ACT team’s shared multidisciplinary records. IDDT’s target population has elevated rates of contact with the criminal justice system — a well-documented epidemiological reality for people with severe mental illness and co-occurring SUD in the United States, particularly in the absence of adequate community treatment resources. Mental health diversion programs, mental health courts, and criminal justice diversion initiatives specifically target this population, often using ACT-like service models as the treatment structure for divertees. The ACT team meeting narrations document the patient’s psychiatric status, substance use behavior, crisis history, medication adherence, and community functioning at regular intervals throughout the treatment course.

In criminal proceedings involving an IDDT patient — whether as a defendant, a victim, or a witness — the ACT team meeting narrations constitute a comprehensive third-party record of the patient’s clinical status and behavioral history, maintained by a cloud AI scribe vendor as a business record external to the treating team’s own records. A criminal defense attorney seeking evidence of their client’s mental state at the time of an offense may subpoena the vendor for the ACT team meeting narrations covering the relevant period — obtaining the team’s documented assessment of the patient’s psychosis severity, medication adherence, and substance use status in the weeks preceding the offense. A prosecutor seeking to establish that a defendant with SMI was in substance-induced psychosis rather than a genuine SMI-driven mental state at the time of the offense may seek the integrated relapse analysis narrations as evidence of the pattern of substance-induced decompensation in the patient’s history. In mental health diversion proceedings, the stage-based assessment and persuasion stage session narrations document the patient’s motivational stage for SUD treatment at each point in the treatment course — documentation that diversion program monitors may use to assess compliance with treatment engagement requirements. The multi-provider structure of the ACT team meeting record — combining the psychiatrist’s clinical assessment, the case manager’s community contact report, and the substance use specialist’s SUD update in a single document — means that a subpoena served on the vendor for this record produces a comprehensive clinical snapshot of the patient that no individual treating provider could produce from their own records alone, because the integrated record combines all team members’ contributions into a single business document that the vendor maintains regardless of which individual clinician’s notes it was derived from.

This is post #236 in the TherapyDraft series examining the credential bodies associated with specific therapy modalities and the vendor archive record types those modalities generate when cloud AI scribes are used in clinical practice. The analysis focuses on the structural characteristics of clinical documentation — what specific record types each modality generates, why those records are structurally absent from all prior posts in the series, and in which adversarial proceedings those records are most likely to surface. Nothing in this post constitutes legal advice. Practitioners with questions about the application of HIPAA, psychotherapist-patient privilege, or state practice act requirements to their specific clinical documentation practices should consult qualified legal counsel.

TherapyDraft is a HIPAA-by-architecture therapy note tool for private-practice clinicians on macOS. Audio, transcript, and note never open a network socket. Join the waitlist.